TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

Biotech firm Novavax dropped 9.1% after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...

But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...

(Reuters) -U.S. stock index futures edged lower on Tuesday after Wall Street's rally over the past few days following election results as traders awaited key inflation data later in the week for more ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Major Wall Street indices closed lower on Tuesday as investors booked some profits from a post-election rally and turned ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

People reporting long-COVID symptoms had elevated levels of cytokines ... The FDA concluded that the event was not related to ...